A large scale met-analysis of 45 randomized controlled trials (a total of 20,027 patients) associated with nine FDA-approved VEGFR-TKIs demonstrates Lenvatinib, followed by vandetanib, cabozantinib, vxitinib, pazopanib, sorafenib, sunitinib, regorafenib and nintedanib had the greatest probability of producing all grades cardiovascular incident and hypertension [24]. The gene discussed is KDR; the disease is Hypertension.